{"id":40562,"date":"2025-09-02T14:21:14","date_gmt":"2025-09-02T06:21:14","guid":{"rendered":"https:\/\/flcube.com\/?p=40562"},"modified":"2025-09-02T14:21:15","modified_gmt":"2025-09-02T06:21:15","slug":"fosun-launches-futuoning-first%e2%80%91in%e2%80%91class-cdk4-6-inhibitor-for-hr%e2%80%91positive-breast-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=40562","title":{"rendered":"Fosun Launches Futuoning, First\u2011In\u2011Class CDK4\/6 Inhibitor for HR\u2011Positive Breast Cancer"},"content":{"rendered":"\n<p><strong>Shanghai Fosun Pharmaceutical (Group) Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2196:HKG\">HKG: 2196<\/a>, <a href=\"SHA: 600196\">SHA: 600196<\/a>) announced the nationwide launch of its Category\u202f1 drug, <strong>fovinaciclib (trade name: Futuoning)<\/strong>. The oral CDK4\/6 inhibitor, coded <strong>FCN\u2011437c<\/strong>, is the first Chinese\u2011developed agent of its class and is now available across the country.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-highlights\">Product Highlights<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism of Action<\/strong> \u2013 Highly selective inhibition of cyclin\u2011dependent kinase\u202f4\/6, blocking cell\u2011cycle progression in hormone\u2011responsive breast cancer cells.<\/li>\n\n\n\n<li><strong>Combination Strategy<\/strong> \u2013 Approved for use with <strong>fulvestrant<\/strong> in HR\u2011positive, HER2\u2011negative metastatic breast cancer that has progressed after prior endocrine therapy.<\/li>\n\n\n\n<li><strong>Oral Administration<\/strong> \u2013 Once\u2011daily dosing improves patient convenience and adherence compared with intravenous CDK4\/6 inhibitors.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>NMPA Approval<\/strong> \u2013 The National Medical Products Administration granted approval in May\u202f2025, designating Futuoning as a Category\u202f1 anti\u2011cancer medication.<\/li>\n\n\n\n<li><strong>Clinical Evidence<\/strong> \u2013 Phase\u202fIII data demonstrated a 35\u2011day improvement in progression\u2011free survival versus fulvestrant alone, with a manageable safety profile.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact\">Market Impact<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Addressable Population<\/strong> \u2013 China\u2019s HR\u2011positive, HER2\u2011negative metastatic breast cancer cohort exceeds 300,000 patients, representing a significant unmet need.<\/li>\n\n\n\n<li><strong>Competitive Edge<\/strong> \u2013 As the first domestically developed CDK4\/6 inhibitor, Futuoning offers a cost\u2011effective alternative to international products such as palbociclib and ribociclib.<\/li>\n\n\n\n<li><strong>Strategic Partnerships<\/strong> \u2013 Fosun plans to collaborate with leading oncology hospitals to accelerate adoption and gather real\u2011world evidence.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-future-outlook\">Future Outlook<\/h2>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Real\u2011World Data Collection<\/strong> \u2013 Post\u2011market surveillance will refine dosing recommendations and support health\u2011technology assessments.<\/li>\n\n\n\n<li><strong>Global Expansion<\/strong> \u2013 Fosun is exploring regulatory submissions in the United States and European Union to broaden access.<\/li>\n\n\n\n<li><strong>Pipeline Synergy<\/strong> \u2013 The success of Futuoning will bolster Fosun\u2019s portfolio of targeted therapies, reinforcing its position as a leading Chinese biopharma innovator.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (HKG: 2196, SHA: 600196) announced the nationwide launch of&#8230;<\/p>\n","protected":false},"author":1,"featured_media":40564,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[159,893,40,892],"class_list":["post-40562","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-fosun-pharmaceutical","tag-hkg-2196","tag-market-launch","tag-sha-600196"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Fosun Launches Futuoning, First\u2011In\u2011Class CDK4\/6 Inhibitor for HR\u2011Positive Breast Cancer - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai Fosun Pharmaceutical\u2019s oral CDK4\/6 inhibitor **fovinaciclib (Futuoning)** has gone nationwide in China. Approved by the NMPA in May\u202f2025, it pairs with fulvestrant to treat HR\u2011positive, HER2\u2011negative metastatic breast cancer that has progressed after endocrine therapy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=40562\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fosun Launches Futuoning, First\u2011In\u2011Class CDK4\/6 Inhibitor for HR\u2011Positive Breast Cancer\" \/>\n<meta property=\"og:description\" content=\"Shanghai Fosun Pharmaceutical\u2019s oral CDK4\/6 inhibitor **fovinaciclib (Futuoning)** has gone nationwide in China. Approved by the NMPA in May\u202f2025, it pairs with fulvestrant to treat HR\u2011positive, HER2\u2011negative metastatic breast cancer that has progressed after endocrine therapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=40562\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-02T06:21:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-02T06:21:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0207.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40562#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40562\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Fosun Launches Futuoning, First\u2011In\u2011Class CDK4\\\/6 Inhibitor for HR\u2011Positive Breast Cancer\",\"datePublished\":\"2025-09-02T06:21:14+00:00\",\"dateModified\":\"2025-09-02T06:21:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40562\"},\"wordCount\":281,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40562#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0207.webp\",\"keywords\":[\"Fosun Pharmaceutical\",\"HKG: 2196\",\"Market launch\",\"SHA: 600196\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40562#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40562\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=40562\",\"name\":\"Fosun Launches Futuoning, First\u2011In\u2011Class CDK4\\\/6 Inhibitor for HR\u2011Positive Breast Cancer - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40562#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40562#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0207.webp\",\"datePublished\":\"2025-09-02T06:21:14+00:00\",\"dateModified\":\"2025-09-02T06:21:15+00:00\",\"description\":\"Shanghai Fosun Pharmaceutical\u2019s oral CDK4\\\/6 inhibitor **fovinaciclib (Futuoning)** has gone nationwide in China. Approved by the NMPA in May\u202f2025, it pairs with fulvestrant to treat HR\u2011positive, HER2\u2011negative metastatic breast cancer that has progressed after endocrine therapy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40562#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40562\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40562#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0207.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0207.webp\",\"width\":1080,\"height\":608,\"caption\":\"Fosun Launches Futuoning, First\u2011In\u2011Class CDK4\\\/6 Inhibitor for HR\u2011Positive Breast Cancer\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40562#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Fosun Launches Futuoning, First\u2011In\u2011Class CDK4\\\/6 Inhibitor for HR\u2011Positive Breast Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Fosun Launches Futuoning, First\u2011In\u2011Class CDK4\/6 Inhibitor for HR\u2011Positive Breast Cancer - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai Fosun Pharmaceutical\u2019s oral CDK4\/6 inhibitor **fovinaciclib (Futuoning)** has gone nationwide in China. Approved by the NMPA in May\u202f2025, it pairs with fulvestrant to treat HR\u2011positive, HER2\u2011negative metastatic breast cancer that has progressed after endocrine therapy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=40562","og_locale":"en_US","og_type":"article","og_title":"Fosun Launches Futuoning, First\u2011In\u2011Class CDK4\/6 Inhibitor for HR\u2011Positive Breast Cancer","og_description":"Shanghai Fosun Pharmaceutical\u2019s oral CDK4\/6 inhibitor **fovinaciclib (Futuoning)** has gone nationwide in China. Approved by the NMPA in May\u202f2025, it pairs with fulvestrant to treat HR\u2011positive, HER2\u2011negative metastatic breast cancer that has progressed after endocrine therapy.","og_url":"https:\/\/flcube.com\/?p=40562","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-02T06:21:14+00:00","article_modified_time":"2025-09-02T06:21:15+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0207.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=40562#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=40562"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Fosun Launches Futuoning, First\u2011In\u2011Class CDK4\/6 Inhibitor for HR\u2011Positive Breast Cancer","datePublished":"2025-09-02T06:21:14+00:00","dateModified":"2025-09-02T06:21:15+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=40562"},"wordCount":281,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=40562#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0207.webp","keywords":["Fosun Pharmaceutical","HKG: 2196","Market launch","SHA: 600196"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=40562#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=40562","url":"https:\/\/flcube.com\/?p=40562","name":"Fosun Launches Futuoning, First\u2011In\u2011Class CDK4\/6 Inhibitor for HR\u2011Positive Breast Cancer - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=40562#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=40562#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0207.webp","datePublished":"2025-09-02T06:21:14+00:00","dateModified":"2025-09-02T06:21:15+00:00","description":"Shanghai Fosun Pharmaceutical\u2019s oral CDK4\/6 inhibitor **fovinaciclib (Futuoning)** has gone nationwide in China. Approved by the NMPA in May\u202f2025, it pairs with fulvestrant to treat HR\u2011positive, HER2\u2011negative metastatic breast cancer that has progressed after endocrine therapy.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=40562#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=40562"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=40562#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0207.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0207.webp","width":1080,"height":608,"caption":"Fosun Launches Futuoning, First\u2011In\u2011Class CDK4\/6 Inhibitor for HR\u2011Positive Breast Cancer"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=40562#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Fosun Launches Futuoning, First\u2011In\u2011Class CDK4\/6 Inhibitor for HR\u2011Positive Breast Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0207.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40562","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=40562"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40562\/revisions"}],"predecessor-version":[{"id":40565,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40562\/revisions\/40565"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/40564"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=40562"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=40562"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=40562"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}